Disposition of 5000 shares by Robert Blum of Cytokinetics at 6.67 subject to Rule 16b-3
| CYTK Stock | USD 49.19 0.17 0.34% |
About 61% of Cytokinetics' investor base is looking to short. The analysis of the overall investor sentiment regarding Cytokinetics suggests that many traders are alarmed. Cytokinetics' investing sentiment shows overall attitude of investors towards Cytokinetics.
Cytokinetics |
Filed transaction by Cytokinetics Director, Officer: President & Ceo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cytokinetics Fundamental Analysis
We analyze Cytokinetics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytokinetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytokinetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Cytokinetics is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Cytokinetics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cytokinetics stock to make a market-neutral strategy. Peer analysis of Cytokinetics could also be used in its relative valuation, which is a method of valuing Cytokinetics by comparing valuation metrics with similar companies.
Peers
Cytokinetics Related Equities
| RLAY | Relay Therapeutics | 3.39 | ||||
| BPMC | Blueprint Medicines | 1.35 | ||||
| RVMD | Revolution Medicines | 0.63 | ||||
| TERN | Terns Pharmaceuticals | 0.70 | ||||
| DYN | Dyne Therapeutics | 0.77 | ||||
| XFOR | X4 Pharmaceuticals | 1.33 | ||||
| PLRX | Pliant Therapeutics | 2.59 | ||||
| ABOS | Acumen Pharmaceuticals | 2.63 | ||||
| ARVN | Arvinas | 2.88 | ||||
| BDTX | Black Diamond | 3.18 | ||||
| STOK | Stoke Therapeutics | 4.09 | ||||
| EWTX | Edgewise Therapeutics | 4.18 | ||||
| AMLX | Amylyx Pharmaceuticals | 5.54 | ||||
| INZY | Inozyme Pharma | 5.86 |
Check out Cytokinetics Hype Analysis, Cytokinetics Correlation and Cytokinetics Performance. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.